Toll-like receptor 9 agonists as cancer therapeutics

Author： Holtick Udo   Scheulen Max E   von Bergwelt-Baildon Michael S   Weihrauch Martin R  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.3, 2011-03, pp. : 361-372

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Toll-Like Receptor Agonists as Adjuvants for HIV Vaccines

By  

Current Medicinal Chemistry, Vol. 18, Iss. 33, 2011-11 ,pp. : 5079-5082

Bentham Science Publishers

Access to resources Recommend Favorite

A Review of the Role of CpG Oligodeoxynucleotides as Toll-Like Receptor 9 Agonists in Prophylactic and Therapeutic Vaccine Development in Infectious Diseases

By Gupta Kaveri  

Drugs in R&D, Vol. 9, Iss. 3, 2008-01 ,pp. : 137-145

Adis International

Access to resources Recommend Favorite

Toll-like receptor agonists: a patent review (2011 – 2013)

By Hussein Waleed M   Liu Tzu-Yu   Skwarczynski Mariusz   Toth Istvan  

Expert Opinion on Therapeutic Patents, Vol. 24, Iss. 4, 2014-04 ,pp. : 453-470

Informa Healthcare

Access to resources Recommend Favorite

Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections

By  

Anti-Infective Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Infective Agents), Vol. 10, Iss. 5, 2011-10 ,pp. : 327-338

Bentham Science Publishers

Access to resources Recommend Favorite

Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections

By  

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 10, Iss. 5, 2012-10 ,pp. : 327-338

Bentham Science Publishers

Access to resources Recommend Favorite